A B S T R A C T
Background. In the last decade, there has been an increase in the use of anti-angiogenic drugs as treatment for metastatic malignancies. However, use of these targeted therapies could induce both glomerular and tubular damage. Also during targeted therapy, the lysosomal protease cathepsin D is released from the tumour, which is inhibited by the protease inhibitor cystatin C. The aim of this study is to determine if use of cystatin C-estimated glomerular filtration rate (eGFR) is applicable to a patient cohort treated with targeted agents. Methods. A cohort of 80 patients with various malignancies were continuously recruited and prospectively analysed. Serum and urinary biochemical analytes for renal toxicities were assessed at different time points during treatment. The association between serum cystatin C and cathepsin D was also determined. Results. A decrease in serum cystatin C concentrations (1.03 versus 0.90 mg/L; P < 0.001), together with an increase in cystatin C-eGFR (71 versus 89 mL/min/1.73 m 2 ; P ¼ 0.002) was observed during therapy, compared with baseline. This decrease in cystatin C concentrations was correlated with cathepsin D (r ¼ 0.307; P < 0.001), which was released from the tumour during targeted therapy. Further analysis demonstrated cathepsin D-mediated proteolysis of cystatin C in serum.
Conclusions. Cystatin C concentrations were decreased during targeted therapy due to cathepsin D-mediated proteolysis. Cystatin C-eGFR is therefore not considered a suitable marker for assessing kidney function in oncology patients, and other techniques to estimate the GFR have to be applied in this patient population.
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I N T R O D U C T I O N
Colorectal carcinoma (CRC) and renal cell carcinoma (RCC) account for 12.1% of all malignancies worldwide, with 1 360 000 and 338 000 estimated new cases globally in 2012, respectively. With 694 000 and 144 000 deaths annually, CRC and RCC are the 4th and 16th leading causes of cancer-related deaths worldwide, respectively [1] .
In the last decade, there has been an increase in the use of anti-angiogenic drugs for the treatment of metastatic CRC or RCC. Approval of these new targeted agents showed improved effectiveness and progression-free survival rates. The angiogenesis inhibitor bevacizumab targeting vascular endothelial growth factor is used extensively in metastatic CRC and RCC [2] [3] [4] . In addition, several multitarget tyrosine kinase inhibitors (TKIs), such as sunitinib, sorafenib, pazopanib and axitinib, as well as the mammalian target of rapamycin (mTOR) inhibitor everolimus [5] , have shown their effectiveness in metastatic RCC [6] [7] [8] [9] [10] [11] .
Use of these targeted therapies can induce both glomerular and tubular damage in the kidneys [12, 13] , due to targeting of vascular endothelial growth factor and other targets, e.g. platelet-derived growth factor, that are also expressed on the normal nephron [14] . Several large trials have reported kidney-related adverse events as a result of administration of targeted therapies. Bevacizumab was shown to cause mild to severe proteinuria in up to 71% of metastatic RCC patients, of which 15% with severe proteinuria with a protein extraction ratio greater than 3.5 g/L [2, 3] . In metastatic CRC treated with bevacizumab, mild to severe proteinuria occurred in 10-43% of cases, of which up to 6.3% had severe proteinuria [4, [15] [16] [17] . Mild to severe proteinuria was also reported in cases of metastatic RCC treated with sorafenib (8%), pazopanib (10%) and axitinib (13%) [7, 11] . Moreover, increased serum creatinine concentrations were observed in patients treated with sunitinib (46-70%), sorafenib (41%), pazopanib (32%), axitinib (55%) and everolimus (50%) [5, [8] [9] [10] , thus showing kidney injury as an important side effect of targeted therapies.
In order to monitor kidney function, the estimated glomerular filtration rate (eGFR) is used, based on serum creatinine or serum cystatin C concentrations. Cystatin C is a 13.3-kDa nonglycosylated member of the cystatin superfamily of cysteine protease inhibitors, which acts as a pro-survival protein in cells under stress conditions. As this protein is fully catabolized in the proximal renal tubule and not returned into the circulation after glomerular filtration, it stands as an ideal marker to estimate the GFR. Under normal conditions, cystatin C-eGFR is less influenced by age, gender, muscle mass and ethnicity, and is therefore very useful in early therapeutic interventions [18] [19] [20] . However, contradictory results have been described in the literature on the biological variation of cystatin C and creatinine in serum, which raises the question of which GFR estimations are applicable to the monitoring of kidney function during therapy [21] [22] [23] [24] [25] . A recent study showed evidence of the proteolytic effect of tumour-released cathepsin D on cystatin C in breast cancer [26] . Thus, one possible explanation for the biological variation of cystatin C is the release of the lysosomal aspartyl protease cathepsin D, which cleaves cystatin C, thus reducing the activity of cystatin C [27, 28] .
The aim of this study was to determine whether estimated GFRs using cystatin C are applicable to monitor kidney function in patients treated with the targeted agents bevacizumab, a TKI or an mTOR inhibitor.
M A T E R I A L S A N D M E T H O D S
Subjects
From April 2013 to November 2016, a cohort of 80 patients presenting to the departments of Medical Oncology and Gastroenterology of Ghent University Hospital, who were treated with a targeted agent [bevacizumab (with FOLFOX or FOLFIRI chemotherapy), a TKI or an mTOR inhibitor], were continuously recruited and prospectively analysed. Upon commencement of targeted therapy, biochemical evaluation was performed at baseline (before treatment initiation), and subsequently after 2, 4 and 8 weeks of therapy. Informed consent was given by all participants and the study was approved by the local Ethics Committee (Belgian registration number: B670201214356).
Sampling
Serum samples (total volume of 6 mL each) were collected Blood samples were allowed to coagulate for 30 min, then centrifuged at 870 g for 10 min and immediately stored at À20 C for subsequent analyses. The samples were analysed for serum creatinine and serum cystatin C concentrations within 1 week of sampling. Rest fractions (were stored for up to 3 years at À80 C) were thawed and analysed for cathepsin D concentrations using enzyme-linked immunosorbent assay (ELISA).
A spot urine sample was collected at each study visit. A total of 5 mL of each urine sample was transferred to an ultraclear polypropylene storage tube, centrifuged at 870 g for 10 min and divided into two aliquots: 2 mL for urinary biochemical analysis and 8 mL for urine flow cytometry. Urinary biochemical analysis included the following analytes: total protein, creatinine, albumin and a1-microglobulin.
Biochemistry
Total urinary protein concentrations were measured using the robust dye binding method, Total Protein Reagent Pyrogallol Red Method with sodium dodecyl sulfate reagent, on Cobas V R 8000 Modular P Analyser Series (Roche Diagnostics GmbH, Mannheim, Germany). Urinary a1-microglobulin was assayed using a Cobas reg; 8000 Modular P Analyser. Serum and urinary creatinine concentrations were determined using the Roche enzymatic method. All reagents and controls are commercially available (Instruchemie BV, Delfzijl, The Netherlands). Protein concentrations were expressed in milligram per gram of urinary creatinine.
Urinary immunoglobulin G and albumin concentrations and serum cystatin C concentrations were determined using immunonephelometry on a BN Nephelometer II Analyser (Siemens Healthcare, Marburg, Germany). All reagents and controls are commercially available (Siemens Healthcare, Marburg, Germany). Albumin concentrations were expressed in milligram per gram of urinary creatinine.
The GFR was determined using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine 2009 equation [29] or CKD-EPI cystatin C 2012 equation [30] . The delta GFR (DGFR) was calculated by subtracting the cystatin CeGFR from the creatinine-eGFR.
Urine flow cytometry was performed using a Sysmex UF1000i V R urine flow cytometer (Sysmex Corporation, Kobe, Japan). The method is based on laser flow cytometry that performs automated microscopic analysis, automatically detecting, identifying and counting epithelial cells and small round cells [31] .
Human cathepsin D ELISA
As it was previously reported that cystatin C can be hydrolysed by the lysosomal proteinase cathepsin D [26] , we performed ELISA assays, according to the manufacturer's instructions, using the Abcam ELISA kit (reference ab119586, Abcam plc, Cambridge, UK), to measure serum cathepsin D concentrations. All buffers and reagents are available in the commercial ELISA kit. Absorbance was measured at a wavelength of 450 nm using a spectrophotometer (Polarstar, BMG Labtech, Offenburg, Germany).
To assess whether cathepsin D mediates proteolysis of cystatin C and whether cathepsin D can be detected using ELISA during this biological interaction, increasing concentrations [26, 32] .
Statistical analysis
Sample size calculation (power ¼ 95%, significance level ¼ 5%) showed the number of patients needed for repeated measurements to be equal to 74. Data from repeated measurements were pooled into one overall group ('during therapy'). Normal distribution was assessed using D'Agostino-Pearson test. Differences in parameters between baseline and during therapy were analysed using independent sample Student's t-test or Mann-Whitney U-test.
Correlation between DGFR and serum cathepsin D concentrations was determined by linear regression. P-values of <0.050 were considered statistically significant. Statistical analyses were performed with G*Power version 3.1.9.2 (Heinrich Heine University, Düsseldorf, Germany), MedCalc Statistical Software version 13.3.1.0 (MedCalc Software, Ostend, Belgium) and GraphPad Prism version 4.7 (GraphPad Software Inc., La Jolla, CA, USA).
R E S U L T S
Patient characteristics
Patient characteristics are summarized in Table 1 . The majority of patients (74%) were diagnosed with metastatic RCC. Therapeutic options consisted of bevacizumab (20%), TKIs (74%) or the mTOR inhibitor everolimus (6%).
Biochemical parameters during therapy with targeted agents
A significant decrease in median serum cystatin C concentrations (1.03 versus 0.90 mg/L; P < 0.001), together with an increase in cystatin C-eGFR (71 versus 89 mL/min/1.73 m 2 ; P ¼ 0.002) was observed during therapy, compared with baseline ( Figure 1A and B) . This was not the case for serum creatinine concentrations (P ¼ 0.985) or creatinine-eGFR (P ¼ 0.903) ( Figure 1C and D) . After adjusting for confounding factors, there was a significant difference in DGFR at baseline, compared with during therapy (P < 0.001; Figure 1E ). Serum cathepsin D concentrations showed a slight decrease during therapy (213 versus 234 mg/L), although not significant (P ¼ 0.245; Figure 1F ). No significant changes in urinary biomarkers were observed (P > 0.050; Figure 1G -J).
Further analysis revealed that patients treated with a TKI showed the greatest changes in cystatin C concentrations (P < 0.001) and cystatin C-eGFR (P ¼ 0.001), whereas no differences in cystatin C concentrations (P ¼ 0.303) and cystatin C-eGFR (P ¼ 0.467) were demonstrated in patients treated with bevacizumab. Accordingly, DGFR was significantly different with time in patients treated with TKIs (P < 0.001), but not in patients treated with bevacizumab (P ¼ 0.355). Changes in serum cathepsin D concentrations during therapy were independent of the targeted therapy administered: TKI (P ¼ 0.519) or bevacizumab (P ¼ 0.482).
Correlation between cystatin C and cathepsin D
Serum cathepsin D concentrations were found to be positively correlated with DGFR for all measurements (r ¼ 0.307, P < 0.001). Remarkably, this correlation was highly significant at baseline (r ¼ 0.434, P < 0.001) and slightly diminished during therapy (r ¼ 0.250, P ¼ 0.001). All correlations are shown in Figure 2 .
Addition of increasing concentrations of human cathepsin D to a serum sample resulted in total depletion of cystatin C from the serum sample ( Figure 3A) . Comparably, cathepsin D was immunologically undetectable, as only low concentrations were detected despite the addition of increasing cathepsin D concentrations ( Figure 3B ).
D I S C U S S I O N
In this study, we assessed whether use of cystatin C-eGFRs is applicable to monitor kidney function in patients treated with different targeted agents for various malignancies.
Firstly, it was remarkable that serum cystatin C concentrations decreased, while cystatin C-eGFR increased, during therapy with targeted agents. This was most common in patients treated with a TKI, which indicates that kidney function in these patients improved during the treatment period. On the other hand, no changes were observed in serum creatinine concentrations and creatinine-eGFR. Cystatin C is considered to be an ideal marker for the estimation of GFR, especially in early therapeutic intervention and during patient follow-up [18, 21] , although its suitability as a marker for GFR estimation has been questioned due to its properties as a protease inhibitor [33] . However, in the literature, there is no evidence on improved kidney function in patients treated with targeted agents, All data are given as number (%), except for age: median (range). especially those diagnosed with metastatic RCC, whereas treatment with partial nephrectomy was reported to lead to improved kidney function after 3 months [34] . As the DGFR decreased during therapy in these patients, the question remains on the actual underlying cause for the decrease in cystatin C concentrations during therapy with targeted agents.
Loss of cystatin C in serum is probably due to its cleavage by cathepsin D, which is released by the tumour, thus resulting in decreased activity of cystatin C [27, 28] , as previously reported in breast cancer [26] and other non-gynaecological solid tumours [35] . The association between cathepsin D and serum cystatin C in metastatic CRC or metastatic RCC is less clear. In these malignancies, cathepsin D has only been assessed for its possible clinical properties as a diagnostic or prognostic biomarker, with contradictory results [36] [37] [38] [39] [40] . Cathepsin D may function differently in various cancers [41] . Here we demonstrated that cathepsin D released from the tumour during targeted therapy also binds and cleaves cystatin C in our patient population, independent of the type of targeted agent administered.
Surprisingly, cathepsin D concentrations only slightly decreased during targeted therapy, while one would expect the opposite following increased necrosis of tumour cells. The same was true for the correlation between serum cathepsin D concentrations and DGFR. Despite a stronger association at baseline, the correlation decreased during therapy. We therefore hypothesize that cathepsin D is immunologically undetectable in cystatin C proteolysis. This was confirmed by the fact that only low cathepsin D concentrations and no cystatin C concentrations could be measured, despite the addition of increasing concentrations of cathepsin D to the serum sample.
This questions the applicability of cystatin C-eGFR to oncology patients. Despite the fact that this marker is usually less influenced by the presence of confounders in the estimation of the GFR, compared with creatinine-eGFR [18, 21] , it would appear that lysosomal proteases can have a profound impact on cystatin C-eGFR. This has to be evaluated further in various cancers in order to determine with more certainty if cystatin CeGFR is applicable to those patients in whom treatment-related renal toxicities occur frequently. As the administration of targeted agents showed no effect on creatinine-eGFR, it would be more appropriate to use this GFR during follow-up, although creatinine-eGFR also has significant limitations. Since weight loss and cachexia, commonly seen in metastatic RCC patients [42] [43] [44] , have a profound impact on creatinine-based eGFR, no optimal estimation of the GFR currently exists to accurately monitor kidney function during follow-up of cancer patients.
Another remark is that cystatin C concentrations were measured using particle-enhanced nephelometric assay (PENIA). It has been stated that analytical variabilities exist between the PENIA and the particle-enhanced turbidimetric immunoassay (PETIA) for cystatin C measurement. However, the differences between these two assays in determining cystatin C concentrations carry less impact due to the weaker exponential relationship that exists between cystatin C and cystatin C-eGFR [45] [46] [47] . Furthermore, recently published literature also reported that standardization of both assays can result in decreased assay variability and improved performance of cystatin C assays [48] . Nevertheless, future research should be conducted to determine if similar decreases in cystatin C concentrations using PETIA can be found in cancer patients during therapy with targeted agents. Importantly, our research raises an important question of whether or not similar changes in cystatin C concentrations can be found in patients treated with other regimens such as chemotherapy. At first indication, chemotherapy appears to exert no effect on cystatin C concentrations, as no concentration changes were observed in patients treated with bevacizumab plus adjuvant FOLFOX or FOLFIRI chemotherapy. However, in our study, due to the limited number of patients who received this treatment regimen, no definite conclusion could be drawn. As one would expect similar release of lysosomal proteases in other conditions associated with tissue damage, evaluation of cystatin C in other treatments, as well as other cancer forms, is therefore warranted.
Despite the frequent occurrence of renal toxicities from targeted therapy, we observed only minor glomerular and tubular damage during targeted therapy with bevacizumab, TKIs or everolimus, based on urinary analytes. This is somewhat contradictory to findings previously reported in large phase III trials [2-5, 7-11, 15] . A possible explanation for the minimal kidney damage in our patients is the high frequency of renal toxicities already present in these patients at baseline, due to previous therapies with targeted agents.
In conclusion, our study showed that serum cystatin C concentrations decreased during treatment with targeted agents due to proteolysis of cystatin C by cathepsin D, which is released from the tumour during targeted therapy. This effect was found mainly in patients treated with TKIs. Due to this biological interaction between cystatin C and cathepsin D, cystatin C-eGFR is therefore not recommended as a suitable marker of kidney function in cancer patients treated with anti-angiogenic drugs.
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